UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________________

FORM 8-K

______________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of ~~report~~Report (~~Date~~date of earliest event reported): February 25, 2026

EDGEWELL PERSONAL CARE COMPANY

(Exact name of registrant as specified in its charter)


Missouri	1-15401	43-1863181
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

6 Research Drive, Shelton, Connecticut 06484

(Address of principal executive offices)

203-944-5500

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	EPC	New York Stock Exchange

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.~~01.~~02 ~~Completion~~Results of ~~Acquisition~~Operations orand ~~Disposition~~Financial ~~of Assets.~~Condition

On February 29, 2026 ~~(the “Closing Date”)~~, Edgewell Personal Care Company, ~~a Missouri corporation~~ (the “Company”), ~~completed~~issued ~~the~~a ~~previously~~press ~~announced~~release ~~sale~~announcing offinancial ~~its Feminine Care segment (the “Business”), including specified assets~~ and ~~liabilities~~operating ~~related~~results tofor ~~the~~its ~~Business,~~first toquarter ~~Essity Aktiebolag (publ), a listed public limited company incorporated under the Laws~~ of ~~the~~fiscal Kingdom of Sweden (“Buyer”) pursuant to the Asset Purchase Agreement, dated as of November 12, 2025 (the “Purchase Agreement”), by and between the Company and Buyer as previously disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on November 12, 2025 (the “Prior 8-K”)2026. AtThis ~~closing~~press ofrelease ~~the transactions contemplated by the Purchase Agreement (the “Closing”), the Company received from Buyer approximately $340 million in cash in exchange for the sale of the Business, which~~ is ~~subject~~furnished toas ~~post-closing~~Exhibit ~~customary adjustments for inventory, indebtedness and other items, pursuant to the terms of the Purchase Agreement~~99.1 ~~Further,~~hereto ~~in connection with the Closing, the Company~~ and ~~Buyer~~incorporated ~~entered~~herein ~~into~~by a customary transition services agreement for the provision of certain services to support the transition of the Business following the Closing, in each case subject to the terms and conditions set forth thereinreference.

The ~~foregoing~~information ~~description~~contained ofin ~~the~~this ~~Purchase~~Current ~~Agreement~~Report ~~and~~on ~~the~~Form ~~sale~~8-K ofunder Item 2.02, including the ~~Business~~accompanying ~~does~~Exhibit ~~not~~99.1, ~~purport~~is being furnished pursuant to beItem ~~complete~~2.02 of Form 8-K and isshall ~~subject~~not be deemed to ~~and~~be ~~qualified~~"filed" infor ~~its~~purposes ~~entirety~~of bySection ~~reference~~18 toof the ~~full~~Securities ~~text~~Exchange Act of 1934, as amended (the ~~Purchase~~"Exchange ~~Agreement~~Act"), aor ~~copy~~otherwise ofsubject ~~which~~to ~~was~~the ~~filed~~liabilities asof ~~Exhibit~~that 2section.1 toThe ~~the~~information ~~Prior~~contained in this Current Report on Form 8-K ~~and~~under isItem 2.02, including the accompanying Exhibit 99.1, shall not be incorporated ~~herein~~by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

At the 2026 Annual Meeting of Shareholders of the Company (the “Annual Meeting”), held on Thursday, February 5, 2026, the Company’s shareholders approved the adoption of the Edgewell Personal Care Company 3rd Amended and Restated 2018 Stock Incentive Plan (the “3rd A&R 2018 Plan”), which was adopted by the Board of Directors of the Company on November 6, 2025 and became effective on the date of approval by the Company’s shareholders.

The 3rd A&R 2018 Plan amends and restates the Edgewell Personal Care Company 2nd Amended and Restated 2018 Stock Incentive Plan and implements the following material changes:

(1)Increases the number of authorized shares by 2,100,000 shares;

(2)Eliminates the fungible share ratio for all new awards; and

(3)Eliminates provisions regarding awards intended to be qualified performance-based compensation under the previously repealed exception to the $1 million deduction limit under Section 162(m) of the Internal Revenue Code of 1986, as amended.

The 3rd A&R 2018 Plan is described in more detail in “Item 4. Approval of the Company’s 3rd Amended and Restated 2018 Stock Incentive Plan” in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on December 22, 2025. The description of the 3rd A&R 2018 Plan contained herein and in the 2025 Proxy Statement do not purport to be complete and are qualified in their entirety by reference to the full text of the 3rd A&R 2018 Plan, a copy of which is filed as Exhibit 10.1 hereto and is incorporated herein by reference.

Item 5.07 Submission of Matters to a Vote of Security Holders.

As noted in Item 5.02, the Company held its Annual Meeting on Thursday, February 5, 2026. Of the 46,715,107 shares outstanding and entitled to vote at the Annual Meeting, 43,465,774 shares were represented in person or by proxy, constituting a quorum.

The final results for each of the matters submitted to a vote of shareholders at the Annual Meeting are as follows:

Proposal 1: Management's nominees for director were elected to serve until the Annual Meeting of Shareholders to be held in 2027 or until their respective successors are elected and qualified, as set forth in the table below:


Nominee	For	Against	Abstain	Broker Non-Votes
Robert W. Black	40,443,287	409,168	19,233	2,594,086
George R. Corbin	40,443,431	412,808	15,449	2,594,086
Carla C. Hendra	38,649,714	2,195,078	26,896	2,594,086
John C. Hunter, III	40,235,255	618,599	17,834	2,594,086
Rod R. Little	34,629,579	6,227,585	14,524	2,594,086
Rakesh Sachdev	37,167,879	3,675,126	28,683	2,594,086
Swan Sit	40,165,791	679,687	26,210	2,594,086
Stephanie Stahl	40,232,871	613,791	25,026	2,594,086
Gary K. Waring	40,201,209	650,221	20,258	2,594,086

Proposal 2: The appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for fiscal 2026 was ratified by the shareholders as set forth in the table below:


For	Against	Abstain	Broker Non-Votes
42,715,456	698,352	51,966

Proposal 3: The approval, on an advisory (non-binding) basis, of the executive compensation paid to the Company’s named executive officers was approved by the shareholders as set forth in the table below:


For	Against	Abstain	Broker Non-Votes
31,787,030	9,020,992	63,666	2,594,086

Proposal 4: The Company's 3rd Amended and Restated 2018 Stock Incentive Plan, as described in the Company's 2025 Proxy Statement, was approved by the shareholders as set forth in the table below:


For	Against	Abstain	Broker Non-Votes
34,771,839	6,061,275	38,574	2,594,086

Item 7.01 Regulation FD Disclosure.

On February 29, 2026, the Company ~~issued~~posted asupplemental ~~press~~financial ~~release~~information ~~announcing~~relating to its recast continuing and discontinued operations for the ~~Closing~~fiscal year ended September 30, 2025 and interim periods within such fiscal year on its investor relations website at ir.edgewell.com. A copy of ~~the~~this ~~press~~supplemental ~~release~~financial information is furnished as Exhibit 99.12 tohereto ~~this Current Report on Form 8-K~~ and is incorporated herein by reference.

The information contained in this Current Report on Form 8-K under Item 7.01, (including the accompanying Exhibit 99.1)2, is being furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be “"filed”" for purposes of Section 18 of the ~~Securities~~ Exchange Act ~~of 1934~~, ~~as amended (the “Exchange Act”),~~ or otherwise subject to the liabilities of that section. ~~Such~~The information contained in this Current Report on Form 8-K under Item 7.01, including the accompanying Exhibit 99.2, shall not be ~~deemed~~ incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, ~~unless~~except as shall be expressly ~~incorporated~~set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(b) Pro Forma Financial Information.

Attached hereto as Exhibit 99.2 are the following unaudited pro forma condensed consolidated financial information: unaudited pro forma condensed consolidated balance sheet as of September 30, 2025 and unaudited pro forma consolidated statements of earnings for the fiscal years ended September 30, 2025, 2024 and 2023, which reflect the sale of the Business.

(d) Exhibits.

Exhibit No.			Description
2.1*†			Asset Purchase Agreement, dated as of November 12, 2025, by and between Edgewell Personal Care Company and Essity Aktiebolag (publ) (incorporated by reference to Exhibit 2.1 of the Company’s Current Report on Form 8-K, dated November 13, 2025).
10.1			Edgewell Personal Care Company 3rd Amended and Restated 2018 Stock Incentive Plan.
99.1			Press Release of Edgewell Personal Care Company, dated February 29, 2026.
99.2			~~Unaudited~~Supplemental ~~Pro Forma Condensed Consolidated~~ Financial Information, ofdated ~~Edgewell~~February ~~Personal~~9, ~~Care Company~~2026.
104			Cover Page Interactive Data File (embedded within the Inline XBRL document)
104.1			Cover Page Interactive Data File (embedded within the Inline XBRL document).

* Copies of schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish copies of any of the omitted schedules and exhibits upon request by the Securities and Exchange Commission or its staff.

† Certain personally identifiable information has been omitted from this exhibit pursuant to Item 601(a)(6) of Regulation S-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		By:	/s/ Francesca Weissman
			Francesca Weissman
			Chief Financial Officer
			(principal financial officer)
Date:	February 69, 2026

Filing Compare · EDGEWELL PERSONAL CARE Co